Pancreatic Cancer Research

ResearcherUniversity of North DakotaActive in the last 2 years

Binglin Sui

ORCID-verified (high confidence)As of 14 November 2026

Matched on ORCID iD 0000-0003-0376-317X; OpenAlex author ID A5065629406.

Their work

Counts cover pancreatic cancer work only: a researcher’s other papers, trials and grants are not in these records.

Pancreatic cancer papers
2 (first author 1, last author 1)
Pancreatic cancer trials
0
Pancreatic cancer grants
0
Collaborators
2
Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 2

  1. Carrier-free single-molecule hypoxia-activated nanoprodrug of SN38 with ultrahigh drug loading for pancreatic cancer treatment. Last author DOI 10.1039/d5tb01434d↗
  2. Esterase-activatable and GSH-responsive Triptolide Nano-prodrug for the Eradication of Pancreatic Cancer. First author DOI 10.1002/anbr.202100040↗

Closest collaborators

The 2 strongest of 2 ranked by shared papers, trials and grants, with recent and small-team work weighing most.

  1. Amrit Regmi · 1 shared paper, 2025
  2. Peisheng Xu · 1 shared paper, 2021

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.